Patients with MASLD had significant increases in IL-33, CXCL5 and CXCL1, while in the non-MASLD group, CCL11 and CXCL5 significantly increased on day 5. This evidence concerns the gene IL33 and metabolic dysfunction-associated steatotic liver disease.